Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.
Roberto A. Leon Ferre, MD
Advertisement
Articles by Roberto A. Leon Ferre, MD
Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).
Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.
Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses ongoing research in triple-negative breast cancer (TNBC).
Advertisement
Latest Updated Articles
Dr. Leon Ferre Discusses Ongoing Research in TNBCPublished: November 30th 2018 | Updated:
Dr. Leon Ferre on Emerging Therapies in TNBCPublished: January 2nd 2019 | Updated:
Dr. Leon Ferre on Reasons to Explore Biosimilars in OncologyPublished: August 29th 2019 | Updated:
Dr. Leon Ferre on the Results of the Randomized Trial of Oxybutynin for Hot FlashesPublished: December 7th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5